



APPENDIX 4D

For the Half Year Ended 31 December 2015

Results for Announcement to the Market

Current Reporting Period - Half year ended 31 December 2015

Previous Reporting Period - Half year ended 31 December 2014

				31 Dec 2015		31 Dec 2014
Revenue	Down	66.19%	to	\$7,411	from	\$21,922
Loss after tax attributable to members	Down	14.17%	to	(\$2,613,117)	from	(\$3,044,403)
Net loss for the period attributable to members	Down	14.17%	to	(\$2,613,117)	from	(\$3,044,403)

Net Tangible Asset per Security (cents per security)

As at 31 December 2015	0.29
As at 31 December 2014	1.98

Dividends (distribution)	Amount per Security	Franked Amount per Security
Final dividend	n/a	n/a
Previous corresponding period	n/a	n/a

Record date for determining entitlements to dividend	<input type="text" value="n/a"/>
Details of dividend reinvestment plans in operation	<input type="text" value="None"/>
Details of entities over which control has been gained or lost during the period	<input type="text" value="None"/>
Details of Associates and Joint Ventures	<input type="text" value="None"/>

These accounts have been subject to review and there has been no qualification or dispute.

Explanation of the above information:

Refer to the Directors' Report - Review of Operations.

Approved Date: Monday, 29th February 2016



ABN 98 009 234 173

Appendix 4D
Interim Financial Report

For the Half Year ended December 2015

To be read in conjunction with the 30 June 2015 Annual Report

In compliance with Listing Rule 4.2A

Table of Contents

Directors' Report	4
Auditors' Independence Declaration	6
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income	7
Condensed Consolidated Statement of Financial Position	8
Condensed Consolidated Statement of Changes in Equity	9
Condensed Consolidated Statement of Cash Flows	10
Notes to the Condensed Consolidated Financial Statements	11
Directors' Declaration	16
Independent Auditors' Review Report	17
Corporate Directory	19

This Half Year Financial Report does not include all notes of the type normal included in an Annual Financial Report. Accordingly, this report is to be read in conjunction with the Annual Financial Report for the year ended 30 June 2015 and any public announcements made by Respire Limited (formerly iSonea Limited) during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001 and the ASX Listing Rules.

Directors' Report

The Directors of Respire Limited ("RSH", "Respire" or "the Group") formerly iSonea Limited ("ISN") provide the following Report on the consolidated entity consisting of Respire Limited and the entities it controlled for the half year ended 31 December 2015.

DIRECTORS

The following persons were Directors of the Company during the whole of the half-year and up to the date of this report, unless otherwise stated:

Mr Leon L'Huillier	Executive Chairman
Mr Ross Blair-Holt	Non-Executive Director
Mr David Ashmore	Non-Executive Director
Mr John Ribot-de-Bresac	Non-Executive Director
Dr Timothy Oldham	Non-Executive Director

PRINCIPAL ACTIVITIES

During the financial half-year the principal continuing activities of the consolidated entity consisted of research, development and commercialisation of medical devices, and the production of Mobile Health applications. There were no significant changes in the nature of the Company's principal activities during the Half Year.

REVIEW OF OPERATIONS

The company has incurred a reduced first half loss of \$2,613,117 compared with the same half last year of \$3,044,403. Our cash burn was \$1,502,198 (2014: \$2,894,796) and we had non cash write down of inventories and other current assets of \$940,801 (2014: nil).

Engineering and software development of the AirSonea home monitoring device and app continued throughout the period. Significant firmware upgrades to the device handset were undertaken to fix bugs. The additional costs of firmware upgrades and improved packaging are reflected in an adjustment to the carrying value of the inventories. The company must ensure its products remain at the leading edge of respiratory monitoring technology.

As previously advised, the company is undertaking a research study at the prestigious University of Chicago. This study will collect and record breath sounds data using AirSonea platform from 90 patients across all age groups (infants to geriatrics) under realistic ambient conditions. The study hypothesis is that the AirSonea is at least as accurate (sensitive and specific) in detection and quantifying wheeze as the consensus of: (a) physicians and (b) a panel of technical experts who evaluate these recordings. The study has commenced and the duration of the protocol is anticipated to be 6 months.

The company continues to strictly control its cash burn. It has finalised our Research and Development Tax Concession application and it is awaiting receipt of the \$673,000 in late February or early March, 2016.

The company is proceeding with a \$3 million Shareholder Rights Issue to provide working capital and to further advance commercialisation.

Directors' Report *(Continued...)*

AUDITORS' INDEPENDENCE DECLARATION

A copy of the auditors' independence declaration as required under section 307C of the Corporations Act 2001 is set out on the page 6.

Signed in accordance with a resolution of directors made pursuant to s.306(3) of the Corporations Act 2001.



On behalf of the Directors

Mr Leon L'Huillier

Executive Chairman

Melbourne

Dated this the 29th Day of February 2016.

Auditors' Independence Declaration

Deloitte.

The Board of Directors
Respiri Limited
Level 29, South Tower
525 Collins Street
Melbourne VIC 3000

Deloitte Touche Tohmatsu
ABN 74 490 121 060

550 Bourke Street
Melbourne VIC 3000
GPO Box 78
Melbourne VIC 3001 Australia

DX: 111
Tel: +61 3 9671 7000
Fax: +61 3 9671 7001
www.deloitte.com.au

29 February 2016

Dear Board Members


Respiri Limited (formerly Isona Limited)

In accordance with section 307C of the Corporations Act 2001, I am pleased to provide the following declaration of independence to the directors of Respiri Limited.

As lead audit partner for the review of the financial statements of Respiri Limited for the financial half-year ended 31 December 2015, I declare that to the best of my knowledge and belief, there have been no contraventions of:

- (i) the auditor independence requirements of the Corporations Act 2001 in relation to the review; and
- (ii) any applicable code of professional conduct in relation to the or review.

Yours sincerely



DELOITTE TOUCHE TOHMATSU



Chris Biermann
Partner
Chartered Accountants

Liability limited by a scheme approved under Professional Standards Legislation.

Member of Deloitte Touche Tohmatsu Limited

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the Half Year Ended 31 December 2015

	Note	Consolidated 31 December 2015 \$ AUD	Consolidated 31 December 2014 \$ AUD
Revenue			
Operating Revenue		4,876	495
Non-operating Revenue		2,535	21,427
Total Revenue		7,411	21,922
Expenses			
Amortisation expenses		(93,729)	(65,380)
Consulting, employee and director expenses		(585,084)	(791,200)
Equity-based payment expenses		(360)	(121,400)
Corporate administration expenses		(170,522)	(763,548)
Depreciation expenses		(22,131)	(15,309)
Marketing and promotion expenses		(22,231)	-
Impairment of Inventory and other current assets		(940,801)	-
Research and development expenses		(728,817)	(1,138,039)
Travel expenses		(56,853)	(171,449)
Loss before income tax expense from continuing operations		(2,613,117)	(3,044,403)
Income tax expense		-	-
Loss after income tax for the year		(2,613,117)	(3,044,403)
Other comprehensive income:			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Exchange differences on translation of foreign operations		5,502	27,294
Total comprehensive loss for the year		(2,607,615)	(3,017,109)
Loss attributable to members of the parent entity		(2,613,117)	(3,044,403)
Total comprehensive loss attributable to members of the parent entity		(2,607,615)	(3,017,109)
Loss per share for the year attributable to the members of the parent entity			
Basic loss per share (cents per share)	8	(0.93)	(1.08)
Diluted loss per share (cents per share)	8	(0.93)	(1.08)

The above Condensed Consolidated Statement of Profit or Loss and other Comprehensive Income should be read in conjunction with the accompanying notes.

Condensed Consolidated Statement of Financial Position

As at 31 December 2015

	Note	Consolidated 31 December 2015 \$ AUD	Consolidated 30 June 2015 \$ AUD
ASSETS			
Current Assets			
Cash and cash equivalents		1,428,336	3,008,627
Trade and other receivables		66,037	69,861
Inventories		420,000	777,500
Other		154,587	702,824
Total Current Assets		2,068,960	4,558,812
Non-Current Assets			
Property, plant and equipment		66,326	74,811
Intangible assets	4	467,288	548,489
Other assets		2,909	2,848
Total Non-Current Assets		536,523	626,148
TOTAL ASSETS		2,605,483	5,184,960
LIABILITIES			
Current Liabilities			
Trade and other payables		1,295,987	1,265,366
Other financial liabilities		16,355	19,197
Total Current Liabilities		1,312,342	1,284,563
TOTAL LIABILITIES		1,312,342	1,284,563
NET ASSETS		1,293,141	3,900,397
EQUITY			
Issued capital	6	95,149,981	95,149,981
Reserves		66,007	177,821
Accumulated Losses		(93,922,847)	(91,427,405)
TOTAL EQUITY		1,293,141	3,900,397

The above Condensed Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes.

Condensed Consolidated Statement of Changes in Equity

For the Half Year Ended 31 December 2015

	Issued Capital	Option Reserve	Foreign Currency Translation Reserve	Accumulated Losses	Total
	\$ AUD	\$ AUD	\$ AUD	\$ AUD	\$ AUD
Balance as at 30 June 2014	95,149,981	861,257	(434,520)	(86,500,313)	9,076,405
Loss after income tax expense for the year	-	-	-	(3,044,403)	(3,044,403)
Other comprehensive income for the year, net of tax	-	-	27,294	-	27,294
Total Comprehensive loss for the half-year	-	-	27,294	(3,044,403)	(3,017,109)
<i>Transactions with Equity holders in their capacity as equity holders:</i>					
Options Issued	-	121,400	-	-	121,400
Options Lapsed*	-	(372,675)	-	372,675	-
Balance at 31 December 2014	95,149,981	609,982	(407,226)	(89,172,041)	6,180,696
Balance at 30 June 2015	95,149,981	445,306	(267,485)	(91,427,405)	3,900,397
Loss after income tax expense for the year	-	-	-	(2,613,117)	(2,613,117)
Other comprehensive income for the year, net of tax	-	-	5,502	-	5,502
Total comprehensive loss for the half-year	-	-	5,502	(2,613,117)	(2,607,615)
<i>Transactions with Equity holders in their capacity as equity holders:</i>					
Options Issued	-	359	-	-	359
Options Lapsed*	-	(117,675)	-	117,675	-
Balance at 31 December 2015	95,149,981	327,990	(261,983)	(93,922,847)	1,293,141

* To transfer the value of lapsed/expired options from the reserve to accumulated losses.

The above Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes.

Condensed Consolidated Statement of Cash Flows

For the Half Year Ended 31 December 2015

	Consolidated 31 December 2015	Consolidated 31 December 2014
Note	\$ AUD	\$ AUD
<u>Cash flows from operating activities</u>		
Receipts from customers	3,382	155
Payments to suppliers and employees (inclusive of GST)	(1,496,202)	(2,908,741)
Interest received	1,963	21,427
Net cash flows used in operating activities	(1,490,857)	(2,887,159)
<u>Cash flows related to investing activities</u>		
Payments for purchases of plant and equipment	(11,341)	(7,597)
Net cash flows used in investing activities	(11,341)	(7,597)
<u>Cash flows related to financing activities</u>		
Proceeds from issues of securities	-	29,703
Other	-	(550)
Net cash flows from financing activities	-	29,153
Net (decrease)/increase in cash and cash equivalents	(1,502,198)	(2,865,603)
Cash and cash equivalents at the beginning of the year	3,008,627	8,212,003
Effects of exchange rate changes on cash and cash equivalents	(78,093)	56,721
Cash and cash equivalents at the end of the year	1,428,336	5,403,121

The above Condensed Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes.

Notes to the Consolidated Financial Statements

Note 1 - Statement of Compliance

The half-year financial report is a general purpose financial report prepared in accordance with the Corporations Act 2001 and AASB 134 'Interim Financial Reporting'. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'. The half-year report does not include notes of the type normally included in an annual financial report and shall be read in conjunction with the most recent annual financial report.

Basis of Preparation

The condensed consolidated financial statements have been prepared on the basis of historical cost. Cost is based on the fair values of the consideration given in exchange for assets. All amounts are presented in Australian dollars, unless otherwise noted.

The accounting policies and methods of computation adopted in the preparation of the half-year financial report are consistent with those adopted and disclosed in the company's 2015 annual financial report for the financial year ended 30 June 2015. These accounting policies are consistent with Australian Accounting Standards and with International Financial Reporting Standards.

Going Concern

The financial report has been prepared on the going concern basis, which assumes continuity of normal business activities and the realisation of assets and the settlement of liabilities in the ordinary course of business.

To continue as a going concern, Respi Limited requires:

- the successful raising of additional equity capital; and
- the continued financial support of its major shareholders and directors.

The company is involved in significant development activity and as such expects to be cash absorbing until its technologies are commercialized. In the half year to 31 December 2015, the company recorded losses before taxation of \$ 2,613,117 (2014: \$3,044,403) and experienced negative operating and investing cash flows of \$1,502,198 (2014: \$2,894,756).

The directors believe the going concern basis of preparation to be appropriate given the following reasons:

- The Company is well advanced in relation to a proposed rights issue which is expected to be launched in March 2016. Patersons Securities Limited has been mandated to lead manage the offer and the company will aim to receive approximately \$3 million through the rights issue. Patersons Securities Limited have been mandated to bring in sub-underwriters without whom the offer will not be underwritten. The Company needs to complete the rights issue by 30 June 2016, based on the group's current cash flow forecast.
- The Company has received letters of intent from a major shareholder and all the directors of the company, confirming their intention to invest in the company through the rights issue in an aggregate amount of up to \$1.1 million.
- The directors are confident that the capital raising referred to above or any additional share issues will raise sufficient funds to allow the company to continue implementing its strategy and continue operations for at least 12 months from the date of signing the directors' declaration for the half year ended 31 December 2015.

Given that the capital raising is currently in progress and having carefully assessed the company's ability to effectively manage its expenditures and cash flows from operations, the directors believe that the company will continue to operate as a going concern for at least the next 12 months and therefore it is appropriate to prepare the financial statements on a going concern basis.

Whilst there are uncertainties as to whether the Company will raise sufficient shareholders support from the Rights Issue to fund the current level of activities of the company for at least the next 12 months, the directors have a reasonable expectation that the Company will raise sufficient equity funding for this purpose. These financial statements have therefore been prepared on a going concern basis which contemplates the continuity of normal business activities and the realisation of assets and settlement of liabilities in the ordinary course of business.

Should the Company be unable to achieve the matters set out above, a material uncertainty would exist as to whether the Company will be able to continue as a going concern and therefore whether it will realise its assets and discharge its liabilities in the normal course of business.

The half-year financial report does not include any adjustments relating to the recoverability and classification of recorded asset amounts, or to the amounts and classification of liabilities that might be necessary should the Company not continue as a going concern.

Note 2 - Dividends

No dividends have been declared for the period ended 31 December 2015.

Note 3 - Segment Information

AASB 8 requires operating segments to be identified on the basis of internal reports about components of the Group that are regularly reviewed by the chief operating decision maker in order to allocate resources to the segment and to assess its performance.

Information reported to the Group's Chief Operating Decision Makers for the purposes of resource allocation and assessment of performance is more specifically focused on the geographical locations of the Group's operations.

The Group's reportable segments under AASB 8 are therefore as follows:

- Australia
- Israel

The Australia reportable segment activities include research, development and commercialisation of medical devices, and the production of Mobile Health applications in Australia.

The Israel reportable segment activities include research, development and commercialisation of medical devices, and the production of Mobile Health applications in Israel.

In prior years, the Group has had operations in United States; however these operations ceased during the half year and therefore are no longer reported as a reportable segment.

Information regarding these segments is presented below. The accounting policies of the reportable segments are the same as the Group's accounting policies.

Notes to the Consolidated Financial Statements (Continued...)

31 December 2015	---- Medical Devices ----			Segment Total \$ AUD	Corporate \$ AUD	Total \$ AUD
	Australia \$ AUD	Israel \$ AUD	USA \$ AUD			
Segment Revenue						
External sales	(272)	5,148	-	4,876	-	4,876
Interest revenue	80	-	-	80	2,455	2,535
Total Segment Revenue	(192)	5,148	-	4,956	2,455	7,411
Segment Expenses						
Segment Depreciation Expenses	(3,885)	(6,479)	-	(10,364)	(11,767)	(22,131)
Segment Expenses	(1,479,467)	(509,229)	-	(1,988,696)	(609,701)	(2,598,397)
Total Segment Expense	(1,483,352)	(515,708)	-	(1,999,060)	(621,468)	(2,620,528)
Income Tax Expense	-	-	-	-	-	-
Net Result	(1,483,544)	(510,560)	-	(1,994,104)	(619,013)	(2,613,117)
Assets						
Segment assets	963,414	595,366	-	1,558,780	1,046,703	2,605,483
Total Assets	963,414	595,366	-	1,558,780	1,046,703	2,605,483
Liabilities						
Segment liabilities	569,513	97,290	-	666,803	645,539	1,312,342
Total Liabilities	569,513	97,290	-	666,803	645,539	1,312,342

31 December 2014	---- Medical Devices ----			Segment Total \$ AUD	Corporate \$ AUD	Total \$ AUD
	Australia \$ AUD	Israel \$ AUD	USA \$ AUD			
Segment Revenue						
External sales	340	155	-	495	-	495
Interest Revenue	36	-	-	36	21,391	21,427
Total Segment Revenue	376	155	-	531	21,391	21,922
Segment Expenses						
Segment Depreciation Expenses	(1,345)	(4,488)	(9,357)	(15,190)	(119)	(15,309)
Segment Expenses	(610,216)	603,104	(1,291,698)	(1,298,810)	(1,752,206)	(3,051,016)
Total Segment Expense	(611,561)	598,616	(1,301,055)	(1,314,000)	(1,752,325)	(3,066,325)
Income Tax Expense	-	-	-	-	-	-
Net Result	(611,185)	598,771	(1,301,055)	(1,313,469)	(1,730,934)	(3,044,403)
Assets						
Segment assets	1,847,299	678,812	260,659	2,786,770	4,831,970	7,618,740
Total Assets	1,847,299	678,812	260,659	2,786,770	4,831,970	7,618,740
Liabilities						
Segment liabilities	410,131	79,038	202,426	691,595	746,449	1,438,044
Total Liabilities	410,131	79,038	202,426	691,595	746,449	1,438,044

Notes to the Consolidated Financial Statements (Continued...)

Note 4 - Intangible Assets

	31 December 2015		30 June 2015	
	\$ AUD		\$ AUD	
Intellectual Property				
At cost		1,998,567		1,986,039
Accumulated Amortisation		(1,531,279)		(1,437,550)
		467,288		548,489

Amortisation is charged on a straight line basis over the expected life of the asset and begins when the asset is available for use. The Directors have determined that the asset was available for use on 1 January 2008 and the life of the intangible is 10 years. Intellectual property relates to acquired assets. Remaining useful life of intangible asset is 2 years.

Note 5 - Contingent Liabilities and Assets

There has been no change in contingent liabilities and assets since the last annual reporting date.

Note 6 - Contributed Equity

	31 December 2015		30 June 2015	
	No.	\$ AUD	No.	\$ AUD
Fully Paid Ordinary Shares				
Balance at beginning of year	281,588,816	95,149,981	275,913,955	95,149,981
Share issued from the exercise of options ¹	-	-	5,674,861	-
Total Issued Capital	281,588,816	95,149,981	281,588,816	95,149,981

¹ During June 2014, the Company received requests from option holders for the exercise of 5,674,861 Listed ISNOB Options. These options were converted into shares on 4 July 2014. Monies totalling AUD \$29,703 pertaining to the exercise of these options were not banked until after 30 June 2014.

During the Half year ended 31 December 2015, the Company issued no Fully Paid Ordinary Shares.

Note 7 - Option Reserve

	31 December 2015		30 June 2015	
	No.	\$ AUD	No.	\$ AUD
Options				
Balance at beginning of year	11,793,060	445,306	8,725,964	861,257
Unlisted Options issued during the year	4,000,000	359	10,000,000	121,400
Share issued from the exercise of options	-	-	(5,674,861)	-
Lapse of options due to nil exercise	(650,000)	(117,675)	(1,258,043)	(537,351)
Total Reserves	15,143,060	327,990	11,793,060	445,306

Notes to the Consolidated Financial Statements (Continued...)

During the Half Year ended 31 December 2015 the Company issued the following securities:

Date	Details	No.	Option fair value \$ AUD	Total Value \$ AUD
Unlisted Options				
08 Dec 15	Issue pursuant to Resolutions 4 and 5 approved by shareholders at Company's Annual General meeting on 26th November 2015	4,000,000	0.00009	359
		4,000,000		359

Note 8 - Loss per Share

	31 December 2015	31 December 2014
Basic loss per share (cents)	(0.93)	(1.08)
Diluted loss per share (cents)	(0.93)	(1.08)
a) Net loss used in the calculation of basic and diluted loss per share	(2,613,117)	(3,044,403)
b) Weighted average number of ordinary shares outstanding during the period used in the calculation of basic and diluted loss per share	281,588,816	281,511,078
c) Potential ordinary shares, including options, are excluded from the weighted average number of shares used in the calculations of basic loss per share. Potential ordinary shares are not considered to be dilutive because the conversion of potential ordinary shares into ordinary shares would increase the basic loss per share.		

Note 9 - Net Tangible Assets

	31 December 2015	31 December 2014
Net Tangible Assets	\$825,853	\$5,578,699
Shares (No.)	281,588,816	281,588,816
Net Tangible Assets (Cents)	0.29	1.98

Note 10 - Events Subsequent to Reporting Date

There have not been any matters or circumstances in the financial statements or notes thereto, that have arisen since the end of the financial half year, which significantly affected, or may significantly affect, the operations of the Group, the results of those operations or the state of affairs of the Group in future financial years.

Directors' Declaration

The directors declare that:

- (a) in the directors' opinion, there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable; and
- (b) in the directors' opinion, the attached financial statements and notes thereto are in accordance with the Corporations Act 2001, including compliance with accounting standards and giving a true and fair view of the financial position and performance of the consolidated entity.

Signed in accordance with a resolution of the directors made pursuant to s.303(5) of the Corporations Act 2001.



On behalf of the Directors
Mr Leon L'Huillier
Executive Chairman

Melbourne

Dated this the 29th Day of February 2016.



Deloitte Touche Tohmatsu
ABN 74 490 121 060

550 Bourke Street
Melbourne VIC 3000
GPO Box 78
Melbourne VIC 3001 Australia

DX: 111
Tel: +61 3 9671 7000
Fax: +61 3 9671 7001
www.deloitte.com.au

Independent Auditor's Review Report to the members of Respiri Limited

We have reviewed the accompanying half-year financial report of Respiri Limited (formerly Isona Limited), which comprises the condensed statement of financial position as at 31 December 2015, and the condensed statement of profit or loss and other comprehensive income, the condensed statement of cash flows and the condensed statement of changes in equity for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration of the consolidated entity comprising the company and the entities it controlled at the end of the half-year or from time to time during the half-year as set out on pages 7 to 16.

Directors' Responsibility for the Half-Year Financial Report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the consolidated entity's financial position as at 31 December 2015 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*. As the auditor of Respiri Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Liability limited by a scheme approved under Professional Standards Legislation.

Member of Deloitte Touche Tohmatsu Limited

Deloitte.

Auditor's Independence Declaration

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*. We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of Respire Limited, would be in the same terms if given to the directors as at the time of this auditor's review report.


Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Respire Limited is not in accordance with the *Corporations Act 2001*, including:


- (a) giving a true and fair view of the consolidated entity's financial position as at 31 December 2015 and of its performance for the half-year ended on that date; and
- (b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Emphasis of matter

Without modifying our conclusion, we draw attention to Note 1 in the half year financial report, which indicates that the consolidated entity incurred a loss of \$2,613,117 (2014: \$3,044,403) and experienced net cash outflows from operating and investing activities of \$1,502,198 (2014: \$2,894,756) for the half year ended 31 December 2015. These conditions, along with other matters as set forth in Note 1, indicate the existence of a material uncertainty which may cast significant doubt about the ability of the consolidated entity to continue as a going concern and therefore, whether it will realise its assets and extinguish its liabilities in the ordinary course of business.



DELOITTE TOUCHE TOHMATSU



Chris Biermann
Partner
Chartered Accountants
Melbourne, 29 February 2016

Corporate Directory

AUSTRALIAN COMPANY NUMBER (ACN)

009 234 173

Respiri Limited is a Public Company Limited by shares and is domiciled in Australia.

DIRECTORS

Mr Leon L'Huillier
Mr John Ribot-de-Bresac
Dr Timothy Oldham
Mr David Ashmore
Mr Ross Blair-Holt

Executive Chairman
Non-Executive Director
Non-Executive Director
Non-Executive Director
Non-Executive Director

COMPANY SECRETARIES

Mr Phillip Hains
Mr Peter Vaughan

PRINCIPAL PLACE OF BUSINESS

The Rialto, Level 29,
525 Collins Street,
Melbourne, Victoria
AUSTRALIA 3000
Telephone: + 61 (0)3 9824 5254
Facsimile: + 61 (0)3 9822 7735

REGISTERED OFFICE

The Rialto, Level 29,
525 Collins Street,
Melbourne, Victoria
AUSTRALIA 3000
Telephone: + 61 (0)3 9824 5254
Facsimile: + 61 (0)3 9822 7735

SHARE REGISTRY

Security Transfer Registrars Pty Ltd
770 Canning Highway
Applecross, Western Australia, 6153
Australia
Telephone: +61 (0)8 9315 2333

SOLICITORS

Francis Abourizk Lightowlers
Level 16, 356 Collins Street
Melbourne, Victoria, 3000
Australia

AUDITORS

Deloitte Touche Tohmatsu
550 Bourke Street
Melbourne, Victoria, 3000
Australia

BANKERS

National Australia Bank (NAB)
330 Collins Street,
Melbourne, Victoria, 3000
Australia

WEBSITES

www.respiri.com
www.airsona.com.au

SECURITIES QUOTED

Australian Securities Exchange
- Ordinary Fully Paid Shares (ASX Code: RSH)